LY-CoV555 Funky Results

Quote

anonymous

Guest
Phase 2 treatment of COVID patients with LY-CoV555 mAb only showed a response at the middle dose tested ... kind of a funky result. Generally, one is quite suspicious of a so-called positive effect when there is no evidence of a dose-response curve.

What explanation is being offered to explain this data?
 






You sales people think you're the only ones to read CafePharma?

Let me assure you that LRL scientists do indeed check in here; this doesn't smell right and we all know it ... science is "truth" and somebody needs to start speaking the truth (publicly).

If there was a threshold for response, say the middle dose, why didn't the higher dose also work? Maybe the higher dose wouldn't necessarily be better than the middle dose, but intuitively it should be at least equivalent.

Granted, this was only Phase 2 data, but now it sounds like the company is going to request an Emergency Use Authorization (EUA) - should not happen before Phase 3 data come in.

And then Lilly immediately announces an agreement with Amgen on manufacturing side for mAb production. Hate to think it, but unless there is an answer WHY this data is weird, it makes one wonder if Covid treatment efforts by the company are just an exercise in pumping the stock price up?
 






anonymous said:
You sales people think you're the only ones to read CafePharma?

Let me assure you that LRL scientists do indeed check in here; this doesn't smell right and we all know it ... science is "truth" and somebody needs to start speaking the truth (publicly).

If there was a threshold for response, say the middle dose, why didn't the higher dose also work? Maybe the higher dose wouldn't necessarily be better than the middle dose, but intuitively it should be at least equivalent.

Granted, this was only Phase 2 data, but now it sounds like the company is going to request an Emergency Use Authorization (EUA) - should not happen before Phase 3 data come in.

And then Lilly immediately announces an agreement with Amgen on manufacturing side for mAb production. Hate to think it, but unless there is an answer WHY this data is weird, it makes one wonder if Covid treatment efforts by the company are just an exercise in pumping the stock price up?
Click to expand...
Uhhh no one f’ing cares so please stop
posting your random shit. Thank you.
 






anonymous said:
You sales people think you're the only ones to read CafePharma?

Let me assure you that LRL scientists do indeed check in here; this doesn't smell right and we all know it ... science is "truth" and somebody needs to start speaking the truth (publicly).

If there was a threshold for response, say the middle dose, why didn't the higher dose also work? Maybe the higher dose wouldn't necessarily be better than the middle dose, but intuitively it should be at least equivalent.

Granted, this was only Phase 2 data, but now it sounds like the company is going to request an Emergency Use Authorization (EUA) - should not happen before Phase 3 data come in.

And then Lilly immediately announces an agreement with Amgen on manufacturing side for mAb production. Hate to think it, but unless there is an answer WHY this data is weird, it makes one wonder if Covid treatment efforts by the company are just an exercise in pumping the stock price up?
Click to expand...
 






anonymous said:
You sales people think you're the only ones to read CafePharma?

Let me assure you that LRL scientists do indeed check in here; this doesn't smell right and we all know it ... science is "truth" and somebody needs to start speaking the truth (publicly).

If there was a threshold for response, say the middle dose, why didn't the higher dose also work? Maybe the higher dose wouldn't necessarily be better than the middle dose, but intuitively it should be at least equivalent.

Granted, this was only Phase 2 data, but now it sounds like the company is going to request an Emergency Use Authorization (EUA) - should not happen before Phase 3 data come in.

And then Lilly immediately announces an agreement with Amgen on manufacturing side for mAb production. Hate to think it, but unless there is an answer WHY this data is weird, it makes one wonder if Covid treatment efforts by the company are just an exercise in pumping the stock price up?
Click to expand...
And yes, we, sales performers or “ you sales people,” bank the Lilly payroll thank you. Cash that paycheck and thank a sales person. Your ideas and science are worthless unless one can bring it to fruition. You may have been the nerd at the back of the classroom. But stay there and let sales drive the market to success
 
























The lack of dose-response relationship, specifically the lack of efficacy at the higher dose, could be the result of a patient randomization problem during clinical study. If such is the case, then it means the LY-CoV555 middle dose "efficacy" is meaningless (not real); regardless of whatever p-value you assign.
 






























Top Bottom
Back
Quote